Collecting duct carcinoma

This phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …

This phase 2 trial tests whether the drug sacituzumab govitecan, alone or combined with atezolizumab, can shrink rare tumors of the kidney, bladder, ureters, or penis. About 60 adults with specific rare cancer types will receive the drugs intravenously in 21-day cycles. The study…

This program provides early access to ubamatamab for people with two rare and aggressive cancers: renal medullary carcinoma and epithelioid sarcoma. The drug is given on a case-by-case basis to those who have no other treatment options. The goal is to offer a potential treatment …

This study is testing whether drug-coated balloons work as well as drug-eluting stents for people with blocked heart arteries. About 321 participants will be randomly assigned to one of three treatments. The main goal is to see how well blood flows through the treated arteries af…

This phase 2 trial is testing two drugs—pembrolizumab (Keytruda) and enfortumab vedotin (Padcev)—in people with rare kidney cancers called collecting duct carcinoma and renal medullary carcinoma. About 23 patients with advanced or metastatic disease will receive the combination f…

This study follows 1,100 adults with rare urinary tract cancers, such as unusual bladder, kidney, testicular, or penile cancers. Researchers will collect medical records, blood and tumor samples, and imaging over many years to understand how these cancers grow and respond to trea…